Yi Z G, Yang X H, Ren J J, Peng W H, Liang Q L
Department of Otolaryngology Head and Neck Surgery,Guizhou Provincial People's Hospital.
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2017 Jan;31(1):34-37. doi: 10.13201/j.issn.1001-1781.2017.01.010.
To explore the clinical effects of Flupentixol/Melitracencombined with specific immunotherapy in allergic rhinitis patients with anxiety and depression. Totally ninetynine moderate to severe persistent allergic rhinitis patients with anxiety and depression from October 2014 to Sepetember 2015 were randomly divided into two groups: 45 patients in experimental group (Flupentixol/Melitracen 10.5 mg，QD,treatment last 4 months)and 44 patients in control group.All patients were treated with specific immunotherapy for 1 years. The nasal symptoms score, mini Rhinoconjunctivitis Quality of life questionnaire(MiniRQLQ), Medication score, SAS and SDS score and the clinical curative effect were observed before treatment, after 4 months or one year treatment. The drug reactions were also recorded. The VAS scores, MiniRQLQ scores, medication scores, SAS and SDS scores of patients in two groups who were treated after 4 months and 1 year were significantly reduced than that of patients before treatment.The differences were statistically significant(<0.05).Compared with the control group, nasal symptom scores, MiniRQLQ scores, medication scores, SAS and SDS scores in experimental group were decreased after 4 month or 1 year treatment(<0.05).After 4 months of treatment, the total effective rate of the experimental group was 84.4%, while the control group was 56.8%.After 1 years of treatment, the experimental group excellence rate was 57.8%, while the control group was 22.7%.The differences were statistically significant(<0.05). During the course of treatment, there were thirteen cases of mild adverse reactionsin experimental group (17.7%) and control group(11.4%). There was no significant differences(>0.05). Flupentixol and melitracen combined with specific immunotherapy could sifnificantlly relieve clinical symptom, quality of life and mental depression.is a safe and reliable therapeutic regimen for further improving clinical symptoms,quality of life,mental statusand the clinical efficacy in moderate to severe persistent with anxiety anddepression.
探讨氟哌噻吨/美利曲辛联合特异性免疫疗法对合并焦虑抑郁的变应性鼻炎患者的临床疗效。选取2014年10月至2015年9月的99例中重度持续性变应性鼻炎合并焦虑抑郁患者，随机分为两组：实验组45例（氟哌噻吨/美利曲辛10.5mg，每日1次，治疗4个月），对照组44例。所有患者均接受特异性免疫疗法治疗1年。观察治疗前、治疗4个月及1年后的鼻症状评分、鼻结膜炎生活质量问卷简表（MiniRQLQ）、用药评分、SAS及SDS评分及临床疗效，并记录药物不良反应。两组患者治疗4个月及1年后的VAS评分、MiniRQLQ评分、用药评分、SAS及SDS评分均较治疗前显著降低，差异有统计学意义（<0.05）。治疗4个月及1年后，实验组的鼻症状评分、MiniRQLQ评分、用药评分、SAS及SDS评分均低于对照组，差异有统计学意义（<0.05）。治疗4个月后，实验组总有效率为84.4%，对照组为56.8%。治疗1年后，实验组显效率为57.8%，对照组为22.7%，差异有统计学意义（<0.05）。治疗过程中，实验组出现轻度不良反应13例（17.7%），对照组出现11例（11.4%），差异无统计学意义（>0.05）。氟哌噻吨与美利曲辛联合特异性免疫疗法能显著缓解临床症状、提高生活质量及减轻精神抑郁，是进一步改善中重度持续性变应性鼻炎合并焦虑抑郁患者临床症状、生活质量、精神状态及临床疗效的安全可靠治疗方案。
